-
Omeprazole sulfone-13C,d3，Omeprazole sulfone-13C,d3; Omeprazole sulphone-13C,d3「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Omeprazole metabolite Omeprazole sulfone-13C,d3 is the deuterium and 13C labeled Omeprazole metabolite Omeprazole sulfone[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Omeprazole sulfone-13C,d3 相关抗体:FMO3 Antibody (YA1992)分子量：365.43Formula：C1613CH16D3N3O4SCAS 号：1261393-28-5非标记 CAS：88546-55-8中文名称：奥美拉唑砜-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
Iloperidone metabolite Hydroxy Iloperidone-d3，P88-d3; Hydroxy Iloperidone-d3「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Iloperidone metabolite Hydroxy Iloperidone-d3 is the deuterium labeled Iloperidone metabolite Hydroxy Iloperidone[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Iloperidone metabolite Hydroxy Iloperidone-d3 相关抗体:FMO3 Antibody (YA1992)分子量：431.51Formula：C24H26D3FN2O4CAS 号：1504554-02-2非标记 CAS：133454-55-4中文名称：伊潘立酮代谢物P88杂质-d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (523 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
PIPES-d18，1,4-Piperazinediethanesulfonic acid-d18「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：PIPES-d18 is the deuterium labeled PIPES[1]. PIPES (1,4-Piperazinediethanesulfonic acid) is an important component of PIPES buffer agent used in biochemistry[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：320.48Formula：C8D18N2O6S2CAS 号：352534-95-3非标记 CAS：5625-37-6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Jason Moggridge, et al. Sensitive Detection of Immunoglobulin G Stability Using in Real-Time Isothermal Differential Scanning Fluorimetry: Determinants of Protein Stability for Antibody-Based Therapeutics. Technol Cancer Res Treat. 2017 Dec;16(6):997-1005. [Content Brief]
-
3-(Cyclohexylamino-1-propanesulfonic Acid-d17「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：3-(Cyclohexylamino)-1-propanesulfonic Acid-d17 is the deuterium labeled CAPS[1]. CAPS, cyclohexylaminopropane sulfonic acid, is a surfactant. CAPS can be used as biological buffer (0.05 M, pH 11) for dialysis[2][3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：238.42Formula：C9H2D17NO3SCAS 号：1219804-15-5非标记 CAS：1135-40-6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (533 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Bedard P R, et al. Ion Interaction: The Energetics and Mechanism of The Competitive Behavior Between Two Similarly Charged Molecules. 1. The Effect of Ionic Strength, Acetonitrile and Surfactant Concentration[J]. Journal of Liquid Chromatography, 1985, 8(13):2417-2443.[3]. Oberley TD, et al. The effect of the dimeric and multimeric forms of fibronectin on the adhesion and growth of primary glomerular cells. Exp Cell Res. 1983 May145(2):265-76. [Content Brief]
-
Tricine-d8，三(羟甲基甲基甘氨酸-d8「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Tricine-d8 is the deuterium labeled Tricine[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：187.22Formula：C6H5D8NO5CAS 号：352534-96-4非标记 CAS：5704-04-1中文名称：三(羟甲基)甲基甘氨酸-d8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (522 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
Alectinib-d8，CH5424802-d8; RO5424802-d8; AF802-d8「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Alectinib-d8 is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Alectinib-d8 相关抗体:ALKBH2 Antibody (YA2047)ALKBH4 Antibody (YA2050)ALK-1 Antibody (YA2457)ALKBH1 Antibody分子量：490.67Formula：C30H26D8N4O2CAS 号：1256585-15-5非标记 CAS：1256580-46-7中文名称：艾乐替尼 d8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19(5), 679-690. [Content Brief][3]. Gadgeel S, et al. Alectinib
-
Maraviroc-d6「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Maraviroc-d6 相关抗体:CCR2 AntibodyCD4 AntibodyCCR7 AntibodyMCP1 AntibodyTARBP2 Antibody (YA1433)SAMHD1 Antibody (YA1542)CCL21 Antibody (YA2775)SV40 T Antigen Antibody (YA3256)TARC/CCL17 Antibody (YA1211)CCR6 Antibody (YA1291)CCR8 Antibody (YA1373)CLEC12A Antibody (YA1419)CCL19 Antibody (YA1670)CCL4 beta Antibody (YA2559)Tat SF1 Antibody (YA2886)CCL19 beta Antibody (YA2923)CCL23 Antibody (YA2929)CCR9 Antibody (YA3119)分子量：519.70Formula：C29H35D6F2N5OCAS 号：1033699-22-7非标记 CAS：376348-65-1运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (527 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine rec
-
D-Lyxose-d「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Lyxose-d 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：151.14Formula：C5H9DO5CAS 号：288846-88-8非标记 CAS：1114-34-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (519 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Con
-
D-Lyxose-13C-4「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：D-Lyxose-13C-4 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Lyxose-13C-4 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：151.12Formula：C413CH10O5CAS 号：139657-61-7非标记 CAS：1114-34-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
-
D-Lyxose-13C-3「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：D-Lyxose-13C-3 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Lyxose-13C-3 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：151.12Formula：C413CH10O5CAS 号：83379-39-9非标记 CAS：1114-34-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
-
D-Lyxose-13C-2「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：D-Lyxose-13C-2 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Lyxose-13C-2 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：151.12Formula：C413CH10O5CAS 号：70849-22-8非标记 CAS：1114-34-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
-
DL-Glyceraldehyde-13C,d，甘油醛-13C,d「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：DL-Glyceraldehyde-13C,d is the deuterium and 13C labeled DL-Glyceraldehyde[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.DL-Glyceraldehyde-13C,d 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：92.08Formula：C213CH5DO3CAS 号：72599-69-0非标记 CAS：56-82-6中文名称：甘油醛-13C,d运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (519 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 20
-
DL-Glyceraldehyde-2-13C，甘油醛-13C「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：DL-Glyceraldehyde-2-13C is the 13C labeled DL-Glyceraldehyde[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.DL-Glyceraldehyde-2-13C 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：91.07Formula：C213CH6O3CAS 号：71122-43-5非标记 CAS：56-82-6中文名称：甘油醛-13C运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-
-
DL-Glyceraldehyde-1-13C，甘油醛-13C「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：DL-Glyceraldehyde-1-13C is the 13C labeled DL-Glyceraldehyde[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.DL-Glyceraldehyde-1-13C 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：91.07Formula：C213CH6O3CAS 号：70849-18-2非标记 CAS：56-82-6中文名称：甘油醛-13C运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-
-
D-Allose-13C「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：D-Allose-13C is the 13C labeled D-Allose. D-Allose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Allose-13C 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：181.15Formula：C513CH12O6CAS 号：70849-28-4非标记 CAS：2595-97-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Con
咨询热线
18133906270
德尔塔官方微信